Anti-inflammatory agent
BI 1291583 for Bronchiectasis
This trial evaluates if a medicine (BI 1291583) helps adults with bronchiectasis. Participants take the medicine daily for up to a year & visit study site 9 times. Doctors check if medicine helps reduce symptoms.
Popular Filters
Trials With No Placebo
Behavioural Intervention
Exercise Programs for COPD
This trial aims to compare the effectiveness of a supervised exercise program delivered either onsite or through telehealth for adults with COPD. The study will evaluate outcomes such as breathlessness, exercise capacity, physical function
CFTR Modulator
Trikafta for Bronchiectasis
This trial will test Trikafta, a medication that helps lung proteins work better, on patients with non-cystic fibrosis bronchiectasis. These patients have lung issues similar to cystic fibrosis but do not respond to typical treatments. The goal is to see if Trikafta can improve their lung health by clearing mucus and bacteria from their airways.
Frequently Asked Questions
Introduction to bronchiectasis
What are the top hospitals conducting bronchiectasis research?
Bronchiectasis, a chronic lung condition characterized by the widening and damage of the airways, receives dedicated attention from top hospitals across the United States. The University of Texas Health Science Center at Tyler in Tyler has emerged as a leading institution for bronchiectasis research with two ongoing clinical trials and an impressive track record of five completed trials. Since initiating their first trial in 2011, this Texan hospital has been committed to unraveling new insights into this complex condition. Moving north to Washington D.C., Georgetown University joins the ranks with two active bronchiectasis trials and a recent entry into this field with their inaugural trial in 2022.
Meanwhile, further up the East Coast lies Baltimore's Johns Hopkins Hospital, renowned for its medical expertise. Here too, researchers are actively engaged in studying bronchiectasis through two clinical trials while building upon their initial recorded trial conducted just last year in 2021. Venturing towards Charleston, South carolina brings us to the Medical University of South Carolina—a hub for bronchiectasis studies—where they currently have two active clinical trials underway alongside four previous investigations since embarking on their first trial back in 2011.
Finally, we head southward to Jacksonville's Mayo Clinic in Florida where advanced healthcare meets pioneering research efforts. This esteemed clinic is currently conducting two active bronchiectasis trials that aim to improve our understanding and treatment options for patients living with this condition. Their involvement dates back only until 2020 when they commenced their earliest recorded trial.
While these numbers may seem small compared to other conditions being studied extensively, it is important to recognize that each study represents valuable steps forward toward better management and care for individuals affected by bronchiectasis. These hospitals' commitment reflects a collective dedication within the medical community striving towards improved outcomes and enhanced quality of life for those battling against this challenging lung disease
Which are the best cities for bronchiectasis clinical trials?
The top cities for bronchiectasis clinical trials are New Hyde Park, New york; Clinton, South carolina; Tyler, Texas; Washington, District of Columbia; and Portland, Oregon. These cities host a significant number of active trials focused on studying various treatments for bronchiectasis such as Brensocatib 25 mg, BI 1291583 medium dose arm, ARINA-1, Benralizumab, RHB-204, and others. With a combined total of 28 active trials amongst these cities alone, individuals affected by bronchiectasis have access to ongoing research that may lead to improved therapies and better outcomes.
Which are the top treatments for bronchiectasis being explored in clinical trials?
Bronchiectasis, a condition marked by irreversible damage to the airways, is seeing exciting developments in clinical trials. ARINA-1 takes center stage with one active trial drawing attention since its listing in 2022. Following closely behind is BI 1291583, also making waves with one ongoing trial and three all-time bronchiectasis trials starting from 2022. Additionally, benralizumab and BCG TICE Vaccine are proving their potential with one active and all-time bronchiectasis trials each that were initiated in 2021. These advancements offer hope for patients battling this chronic respiratory disorder as researchers continue to explore new treatment avenues through rigorous clinical investigations.
What are the most recent clinical trials for bronchiectasis?
Recent clinical trials offer hope for individuals with bronchiectasis, a chronic respiratory condition characterized by the widening of airways. Among these trials are BI 1291583, which explores the effectiveness of medium doses in treating bronchiectasis and has entered Phase 2 as of July 21, 2023. Another notable study is Trikafta's Phase 4 trial for bronchiectasis, initiated on April 18, 2023. Additionally, AP-PA02's Phase 2 trial began on January 10, 2023. These innovative investigations aim to advance our understanding and treatment options for this debilitating lung disease.
What bronchiectasis clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of bronchiectasis research, bringing hope to patients suffering from this chronic condition. Notably, a trial sponsored by Pulmatrix Inc., investigating an innovative therapy called Pulmazole, was successfully concluded. This promising treatment aims to provide targeted relief for individuals with bronchiectasis. The completion of this study marks a milestone in advancing our understanding and management of the disease, offering potential new options for those affected by bronchiectasis.